Aarey Drugs & Pharmaceuticals: Intimation/Disclosures under SEBI (Prohibition of Insider Trading) Regulations, 2015
Aarey Drugs & Pharmaceuticals (AAREYDRUGS) filed a disclosure titled "Intimation/Disclosures under SEBI (Prohibition of Insider Trading) Regulations, 2015". The company is valued at about ₹321 crore.
What happened
Aarey Drugs & Pharmaceuticals (AAREYDRUGS) filed a disclosure with the exchanges on 3 October 2026 at 06:27 PM titled "Intimation/Disclosures under SEBI (Prohibition of Insider Trading) Regulations, 2015".
Company snapshot
Aarey Drugs & Pharmaceuticals is a micro-cap company, with a market value of about ₹321 crore.
The stock last traded at ₹103.9, against a 52-week range of ₹50.31–₹107.9 (3.7% below the high).
Before this filing the shares had moved +12.3% over the month and +22.4% over three months. Average daily turnover over the last 20 sessions was about ₹2.42 crore.
Promoters held 42.79% at the end of Q2 FY27, up 5.08% points from the previous quarter. Foreign institutions owned 4.41% and domestic institutions 1.49%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 102 | 1.4 | 0.48 |
| Q2 FY26 | 84 | 1 | 0.72 |
| Q3 FY26 | 96 | 1.3 | 0.2 |
| Q4 FY26 | 189 | 1.6 | 0.55 |
| Q1 FY27 | 45 | 1 | 0.36 |
What history shows
BCEIE's records show 2 previous insider / sast filings from the company since May 2026.
After those filings, the stock fell 0.1% on average the next trading day and was down 4.3% on average after five days (2 filings with price data).
Market-wide, 47 insider / sast filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 38% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 6 Jul 2026 | Disclosure under SEBI Takeover Regulations | +3.7% | −4.3% |
| 1 Jul 2026 | Disclosure under Regulation 31(4) of the Securities and Exchange… | −3.9% | −4.3% |
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.